478 completed, 35 terminated, 24 unknown, 12 withdrawn. 224 Phase 4, 200 Phase 3, 62 Phase 1, 44 Not applicable, 28 Phase 2.
Follow Insulin Glargine: new trials by email Literature Review of Insulin Glargine trials Research Report on Insulin Glargine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp) - Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes | Not applicable | Not yet recruiting | Hallym University | 50 | 2026-08-01 | 2026-07-22 |
| Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection - Type 2 Diabetes | Phase 4 | Not yet recruiting | Yanbing Li | 324 | 2026-03-15 | 2026-02-06 |
| Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs) - Type 2 Diabetes | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1316 | 2025-12-13 | 2026-07-07 |
| Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) Insulin glargine alone, Insulin glargine + insulin lispro - Diabetes in Pregnancy, Gestational Diabetes | Not applicable | Recruiting | Rutgers, The State University of New Jersey | 176 | 2025-11-26 | 2026-04-16 |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes Insulin icodec, Insulin glargine, Insulin aspart - Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | Novo Nordisk A/S | 877 | 2025-08-11 | 2026-09-25 |
| Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes lixisenatide + glargine, Intensive insulin therapy - Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia | Phase 4 | Enrolling by invitation | Medical University of Warsaw | 100 | 2025-07-10 | 2025-09-19 |
| Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects SHR-3167, Insulin glargine - Type 2 Diabetes | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 275 | 2025-01-08 | 2026-06-04 |
| A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus iGlarLixi (insulin glargine/lixisenatide) - Type 2 Diabetes | Phase 4 | Completed | Sanofi | 105 | 2025-01-06 | 2026-07-10 |
| iGlarLixi CGM Study in Chinese T2D Individuals After OADs iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine) - Type 2 Diabetes (T2D) | Phase 4 | Recruiting | Sanofi | 678 | 2024-12-10 | 2026-03-17 |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) Insulin - Gestational Diabetes, Pregnancy Related | Not applicable | Recruiting | Thomas Jefferson University | 430 | 2024-09-01 | 2024-11-22 |
| Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes Insulin - Gestational Diabetes, Pregnancy Related | Not applicable | Recruiting | Thomas Jefferson University | 430 | 2024-09-01 | 2024-11-21 |
| Effect of Topical Insulin on Healing Rate of Pemphigus Lesions insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion | Phase 2 | Completed | Alexandria University | 20 | 2024-06-22 | 2026-03-10 |
| A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes HR17031 injection, insulin glargine - Adult Patients With Type 2 Diabetes | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 393 | 2024-05-08 | 2026-01-13 |
| A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes HR17031 injection, insulin glargine - Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 401 | 2024-04-30 | 2026-01-27 |
| A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes Insulin icodec, Insulin glargine - Diabetes, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 412 | 2024-04-19 | 2026-08-11 |
| A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India Insulin Lispro-aabc, Insulin Glargine - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Eli Lilly and Company | 153 | 2024-04-18 | 2026-09-28 |
| RCT Glargine vs NPH for Treatment of DM in Pregnancy Insulin glargine, insulin NPH - Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Recruiting | Loyola University | 160 | 2024-04-01 | 2024-10-01 |
| A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) IcoSema, Insulin glargine - Type 2 Diabetes | Phase 3 | Completed | Novo Nordisk A/S | 485 | 2024-02-15 | 2026-06-05 |
| Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia Insulin Glargine, Insulin Degludec, Insulin regular - Glycemic Control, Insulin | Not applicable | Completed | Ain Shams University | 90 | 2023-12-01 | 2024-08-05 |
| Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg - Type2diabetes | Phase 3 | Completed | University of Basrah | 243 | 2023-11-01 | 2025-03-30 |
Showing 20 of 565. Sign in to see all of them.
Diabetes Mellitus, Type 2 (354) · Diabetes Mellitus (177) · Diabetes Mellitus, Type 1 (115) · Insulin Resistance (54) · Hyperglycemia (29) · Hypoglycemia (17) · Diabetic Ketoacidosis (7) · Diabetes, Gestational (5) · Glucose Intolerance (5) · Motor Activity (5) · Obesity (5) · Cardiovascular Diseases (4) · Metabolic Diseases (4) · Non-alcoholic Fatty Liver Disease (4) · Prediabetic State (4)
Sanofi (143) · Novo Nordisk A/S (81) · Eli Lilly and Company (74) · Emory University (18) · Merck Sharp & Dohme LLC (14) · AstraZeneca (9) · Jiangsu HengRui Medicine Co., Ltd. (5) · Population Health Research Institute (5) · Adocia (4) · Ain Shams University (3) · Baylor College of Medicine (3) · Geropharm (3) · GlaxoSmithKline (3) · Halozyme Therapeutics (3) · HealthPartners Institute (3)
United States (247) · Germany (116) · Canada (69) · Mexico (68) · Spain (67) · Poland (59) · Russia (58) · India (57) · China (55) · United Kingdom (55) · Hungary (54) · Puerto Rico (52) · France (51) · Romania (51) · Italy (48)
Guillermo Umpierrez, MD (11) · Douglas Muchmore, M.D. (3) · Guillermo E Umpierrez, MD (3) · Karen Barch, B.S. (3)
PMID 33166419, PMID 23130654, PMID 24170235, PMID 26232910, PMID 36542287, PMID 26121451, PMID 26484727, PMID 26663320, PMID 39963952, PMID 24812526, PMID 25081590, PMID 28417532, PMID 28587667, PMID 29167192, PMID 29974618, PMID 35044568, PMID 22236356, PMID 25581159, PMID 28946756, PMID 30160030, PMID 30366067, PMID 36106652, PMID 40186685, PMID 40465144, PMID 18204830, PMID 19366972, PMID 22913891, PMID 23101951, PMID 24622318, PMID 26582052, PMID 26691396, PMID 27161178, PMID 28210866, PMID 29370218, PMID 29430801, PMID 29649539, PMID 29855972, PMID 29895556, PMID 29923298, PMID 30097995, PMID 30262460, PMID 30362250, PMID 30550345, PMID 31114694, PMID 31178433, PMID 31301210, PMID 31705547, PMID 31797522, PMID 31848983, PMID 31865758
2014 (14), 2008 (13), 2009 (13), 2015 (11), 2018 (6), 2016 (5), 2019 (4), 2004 (3), 2017 (3), R01DK077166 (2), U01DK094406 (2), 2005 (1), 2023 (1), K23DK124647 (1), K23HD103875 (1)